The DAPT Study is an independent, large-scale study in size and scope intended to determine the appropriate duration for dual antiplatelet therapy (the combination of aspirin and a second anti-clotting medication to reduce the risk of blood clots) to protect patients from stent thrombosis and major cardiovascular and cerebrovascular events (MACCE) following implantation of drug-eluting coronary stents.
The DAPT Study concept was developed by a group of eight manufacturers (four major stent manufacturers and four manufacturers of antiplatelet medications) who came together to address a U.S. Food and Drug Administration (FDA) request for this post-market study. The Harvard Clinical Research Institute (www.hcri.harvard.edu) is responsible for the scientific conduct and independent analysis of the overall study
